Becton, Dickinson and Company (BDX) fair value analysis
S&P 500 · Updated 2026-10-19
BDX price how computed
Forward Fair Value verdict
UndervaluedBDX is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $183.75
- Sector
- Healthcare
- 12-month range
- $138.67–$193.76
- Market cap
- $50.1B
- From 52-week high
- -5.2%
- Shares outstanding
- 272M
- Rank in Healthcare by discount to fair value
- #38 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Becton, Dickinson and Company is a global medical technology manufacturer that produces and distributes a broad range of medical devices, laboratory equipment, and diagnostic products used in healthcare settings. The company operates in multiple regions including North America, Europe, Asia Pacific, and other international markets, serving hospitals, clinical laboratories, physicians' offices, and patients worldwide.
BDX currently ranks #38 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 13 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $50.1B
- P/E (trailing)
- 14x
- Revenue (TTM)
- $20.8B
- Net margin
- 4.5%
- EPS (TTM)
- $13.00
- Gross margin
- 46.5%
- Debt / equity
- 0.69
- Revenue growth (3-yr avg)
- -0.7%
- Shares outstanding
- 272M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 64 · neutral
- 50-day average
- $183.88
- 200-day average
- $164.10
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $4.20 per share (4 payments)
- Yield on last price
- 2.29%
- Consecutive years of increases
- 26
- Last ex-dividend date
- 2026-09-09
- Last payment date
- 2026-09-30
Earnings how computed
- Next earnings report
- 2026-11-05 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+2.9%)
2026-03 ▲ beat (+4.7%)
2025-12 ▲ beat (+3.9%)
2025-09 ▲ beat (+1.3%)
2025-06 ▲ beat (+7.6%)
2025-03 ▲ beat (+2.1%)
2024-12 ▲ beat (+14.7%)
2024-09 ▲ beat (+1.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 7 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $194
- Target vs last price
- +5.6%
What our data shows for BDX
- Our model validated 17 trailing price-to-earnings windows for BDX, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $138.67–$193.76.
- The 14-day relative strength index sits at a neutral 64.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BDX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BDX news
TickrTrends' derived news-sentiment signal for BDX is currently leaning positive, computed from recent coverage.
- Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look? (insidermonkey.com, 2026-10-14)
TickrTrends take: Becton, Dickinson and Company operates in the Healthcare sector and currently carries a TickrTrends valuation assessment of Undervalued. A yield consideration in the context of an undervalued assessment may signal that the market has not fully priced in the company's fundamentals, which could be relevant for investors focused on valuation metrics. Valuation-focused readers should monitor whether the company's operational performance and cash flow generation justify the current assessment over time. - Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further? (insidermonkey.com, 2026-10-13)
TickrTrends take: Becton Dickinson's significant earnings decline despite modest revenue growth suggests margin compression that investors tracking valuation metrics should monitor closely. Given that TickrTrends currently rates BDX as undervalued in the Healthcare sector, understanding whether this profit deterioration reflects temporary operational headwinds or structural challenges becomes important for assessing whether the undervaluation designation remains justified. The gap between revenue and earnings performance indicates that cost management and operational efficiency will be critical factors to watch in upcoming quarters. - Becton Dickinson (BDX) to Invest $3 Billion in U.S. Medical Supply Production (gurufocus.com, 2026-10-06)
TickrTrends take: Becton Dickinson's commitment to invest 3 billion dollars in U.S. medical supply production represents a significant capital allocation toward domestic manufacturing capacity. This investment signals management confidence in sustained demand for medical supplies and positions the company to benefit from potential reshoring trends in healthcare manufacturing. Given TickrTrends' current undervalued assessment, investors focused on valuation should monitor whether this substantial capital expenditure translates into margin expansion and revenue growth that could justify a higher valuation multiple over the medium term.
More BDX news
- BDX Looks 1.0% Overvalued on GF Value™ as Dividend Sustainability Remains Key (gurufocus.com, 2026-09-21)
What people are saying
Follow the BDX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BDX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), BDX is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is BDX's TickrTrends verdict?
BDX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does BDX compare to other Healthcare stocks?
BDX ranks #38 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is BDX overbought or oversold?
BDX's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does BDX pay a dividend?
Yes. BDX paid $4.20 per share over the last twelve months (4 payments), a 2.29% yield on TickrTrends' last price, and has raised the annual total for 26 consecutive years. The last ex-dividend date was 2026-09-09.
When does BDX report earnings next?
BDX's next earnings report is scheduled for 2026-11-05 (pre-market), per the published earnings calendar.
Does BDX usually beat earnings estimates?
Over its last 8 reported quarters BDX beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BDX?
Of 14 analysts covering BDX, 7 rate it a buy, 7 a hold and 0 a sell - buy-leaning, with a consensus price target of $194 (+5.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
BDX vs BAX · BDX vs BTSG · BDX vs CGON · BDX vs EW · BDX vs INVA